Skip to main content
. 2019 May;15(2):136–144. doi: 10.2174/1573403X15666181205110624

Table 3.

Differences in outcomes between men and women in DOAC trials.

Trial % Women Primary Outcome P Value for Difference in Primary Endpoint Between Women and Men
ARISTOTLE (apixaban) 35 Stroke or systemic embolism 0.60
RE-LY (dabigatran) 37 Stroke or systemic embolism 0.24
ROCKET AF (rivaroxaban) 39.7 Stroke or systemic embolism 0.927